XML 30 R19.htm IDEA: XBRL DOCUMENT
v3.23.3

Fair Value of Financial Instruments | 9 Months Ended
--- | ---
Sep. 30, 2023
Fair Value Disclosures [Abstract] |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature. The Company measures the value of its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment. During the year ended December 31, 2021, Reneo completed its initial public offering. As a result, the fair value of the Company’s investment in Reneo’s common stock now has a readily determinable market value and is no longer eligible for the practical expedient for investments without readily determinable fair market values. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The Company determined that the G42 Promissory Note receivable was level 2 and the fair value measurement was based on the market yield curves. The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2023 and December 31, 2022 (in thousands):
| Balance at September 30, 2023 |  | Quoted Prices in Active Markets for Identical Assets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
Assets: |  |  |  |  |  |  |
Equity securities with readily determinable fair value | $ | 4,387 |  |  | $ | 4,387 |  |  | $ | — |  |  | $ | — |
Total | $ | 4,387 |  |  | $ | 4,387 |  |  | $ | — |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |
Warrant liability, related party (1) | $ | 278 |  |  | $ | — |  |  | $ | — |  |  | $ | 278 |
Total | $ | 278 |  |  | $ | — |  |  | $ | — |  |  | $ | 278 |
| Balance at December 31, 2022 |  | Quoted Prices in Active Markets for Identical Assets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
Assets: |  |  |  |  |  |  |
Equity securities with readily determinable fair value | $ | 1,343 |  |  | $ | 1,343 |  |  | $ | — |  |  | $ | — |
Total | $ | 1,343 |  |  | $ | 1,343 |  |  | $ | — |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |
Warrant liability, related party (1) | $ | 684 |  |  | $ | — |  |  | $ | — |  |  | $ | 684 |
Total | $ | 684 |  |  | $ | — |  |  | $ | — |  |  | $ | 684 |
_____________________________
(1) | Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.
| Changes in Level 3 instruments for the three months ended September 30,
| Balance at January 1 |  | Net Change in fair value included in earnings |  | Purchases / Issuance |  | Sales / Repurchases |  | Balance at September 30,
2023 |  |  |  |  |  |  |  |  |
Warrant liability, related party | $ | 684 |  |  | $ | (406) |  |  | $ | — |  |  | $ | — |  |  | $ | 278 |
Total | $ | 684 |  |  | $ | (406) |  |  | $ | — |  |  | $ | — |  |  | $ | 278 |
2022 |  |  |  |  |  |  |  |  |
Warrant liability, related party | $ | 1,262 |  |  | $ | (221) |  |  | $ | 368 |  |  | $ | — |  |  | $ | 1,409 |
Total | $ | 1,262 |  |  | $ | (221) |  |  | $ | 368 |  |  | $ | — |  |  | $ | 1,409 |
There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and nine months ended September 30, 2023. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other income – related party in the Company’s Condensed Consolidated Statements of Operations. The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company’s current capitalization. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September 30, 2023 and December 31, 2022 were:
| September 30, 2023 |  | December 31, 2022
| Range | Weighted Average |  | Range | Weighted Average
Expected volatility | 68.37% - 77.01% | 76.06% |  | 76.94% - 85.88% | 82.17%
Risk-free interest rate | 4.78% - 5.38% | 4.88% |  | 4.11% - 4.43% | 4.19%
The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September 30, 2023 were:
Expected volatility | 82.38 | %
Expected life of options in years | 3.75
Risk-free interest rate | 4.73 | %
Expected dividend yield | — | %
The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants. Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants and CinRx Warrants. Increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration